Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2017

View Archived Issues

Novel pocket-modified vancomycin analogues show potential as durable and potent antibiotics

Mutations in SCN9A gene linked to diabetic neuropathic pain

FDA accepts Rigel Pharmaceuticals' NDA for fostamatinib disodium

Axovant Sciences' nelotanserin obtains FDA fast track designation

Seattle Genetics halting phase III CASCADE study of vadastuximab talirine

Human umbilical cord mesenchymal stem cells evaluated in ischemic cardiomyopathy trial

EC approves biosimilar rituximab from Sandoz

Next generation diarylquinoline TBAJ-587 displays superior potency against tuberculosis

MedImmune introduces a novel anti-FcRII-a antibody

Engineered grafts show esophageal regeneration ability in a large animal model

Tessa Therapeutics enters alliance with Parker Institute for Cancer Immunotherapy

Cell Medica acquires Catapult Therapy TCR

Abide Therapeutics describes novel MGL/FAAH inhibitors

FDA approves Baxdela for ABSSSI

eFFECTOR Therapeutics identifies new MAP kinase signal-integrating kinase 1/2 inhibitors

Novel USP1 inhibitors identified at FORMA Therapeutics

Clovis Oncology presents positive topline data from phase III ARIEL3 study of rucaparib

ViiV Healthcare presents novel anti-HIV compounds

AstraZeneca, Cancer Research Technology patent GLS inhibitors

Narurapid and Narusus launched in Japan

Enzychem Lifesciences begins phase II trial of EC-18 in CIN

Novartis reports phase III data on RTH-258 in neovascular AMD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 8, 2025.
House passes H.R. 1, restoring R&D tax cuts
BioWorld MedTech
The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
Exercise-mimicking compound offers alternative to GLP-1 therapies
BioWorld
An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
With surface mimicry, molecular glues shed hairpin need
BioWorld Science
Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...